JP2018505899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505899A5 JP2018505899A5 JP2017543785A JP2017543785A JP2018505899A5 JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5 JP 2017543785 A JP2017543785 A JP 2017543785A JP 2017543785 A JP2017543785 A JP 2017543785A JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5
- Authority
- JP
- Japan
- Prior art keywords
- alzheimer
- disease
- mammal
- condition
- cognitive dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 208000010877 cognitive disease Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 2
- 230000007450 amyloidogenic pathway Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117888P | 2015-02-18 | 2015-02-18 | |
| US62/117,888 | 2015-02-18 | ||
| PCT/US2016/018305 WO2016134042A2 (en) | 2015-02-18 | 2016-02-17 | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505899A JP2018505899A (ja) | 2018-03-01 |
| JP2018505899A5 true JP2018505899A5 (OSRAM) | 2019-03-14 |
| JP6830895B2 JP6830895B2 (ja) | 2021-02-17 |
Family
ID=56692299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543785A Active JP6830895B2 (ja) | 2015-02-18 | 2016-02-17 | ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10618899B2 (OSRAM) |
| EP (1) | EP3259274B1 (OSRAM) |
| JP (1) | JP6830895B2 (OSRAM) |
| KR (1) | KR102220260B1 (OSRAM) |
| CN (1) | CN107709326B (OSRAM) |
| AU (1) | AU2016220049C1 (OSRAM) |
| CA (1) | CA2976258C (OSRAM) |
| WO (1) | WO2016134042A2 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134042A2 (en) | 2015-02-18 | 2016-08-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| US11814734B2 (en) | 2019-05-13 | 2023-11-14 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| ES2932481B2 (es) * | 2021-07-09 | 2023-09-11 | Consejo Superior Investigacion | Compuestos inhibidores de la quinasa de tau y tubulina (ttbk) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| ATE221886T1 (de) | 1997-09-02 | 2002-08-15 | Bristol Myers Squibb Pharma Co | Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress |
| WO2001058489A1 (en) | 2000-02-14 | 2001-08-16 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
| AU2003274652A1 (en) | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CA2808630A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| AU2012290116B2 (en) | 2011-08-02 | 2016-11-03 | Buck Institute For Research On Aging | Tropinol esters and related compounds to promote normal processing of APP |
| WO2013026021A2 (en) | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
| CA2867891C (en) | 2012-03-19 | 2021-09-14 | Buck Institute For Research On Aging | App specific bace inhibitors (asbis) and uses thereof |
| US9649317B2 (en) | 2012-09-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies |
| US10202355B2 (en) | 2013-02-12 | 2019-02-12 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| WO2016134042A2 (en) | 2015-02-18 | 2016-08-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
-
2016
- 2016-02-17 WO PCT/US2016/018305 patent/WO2016134042A2/en not_active Ceased
- 2016-02-17 KR KR1020177025850A patent/KR102220260B1/ko active Active
- 2016-02-17 US US15/548,402 patent/US10618899B2/en active Active
- 2016-02-17 JP JP2017543785A patent/JP6830895B2/ja active Active
- 2016-02-17 CA CA2976258A patent/CA2976258C/en active Active
- 2016-02-17 EP EP16752995.7A patent/EP3259274B1/en active Active
- 2016-02-17 CN CN201680017456.6A patent/CN107709326B/zh active Active
- 2016-02-17 AU AU2016220049A patent/AU2016220049C1/en active Active
-
2020
- 2020-02-21 US US16/797,846 patent/US10844071B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017075173A5 (OSRAM) | ||
| MX2024010140A (es) | Nuevos metodos. | |
| AR110747A1 (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2021002322A (es) | Nuevos metodos. | |
| JP2017057230A5 (OSRAM) | ||
| JP2018021046A5 (OSRAM) | ||
| JP2014507446A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2011509252A5 (OSRAM) | ||
| MX2022008181A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
| JP2016522254A5 (OSRAM) | ||
| RU2017105353A (ru) | Соединения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2016512817A5 (OSRAM) | ||
| RU2017107760A (ru) | Соединение | |
| JP2016501219A5 (OSRAM) | ||
| JP2015537009A5 (OSRAM) | ||
| JP2017518982A5 (OSRAM) | ||
| JP2016537338A5 (OSRAM) | ||
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| JP2018505899A5 (OSRAM) | ||
| JP2015516419A5 (OSRAM) | ||
| RU2017139002A (ru) | Пироглутамат вортиоксетина | |
| JP2016537432A5 (OSRAM) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний |